About Scopus BioPharma
Scopus BioPharma is a company based in United States founded in 2019.. Scopus BioPharma has raised $9.34 million across 4 funding rounds. Scopus BioPharma has completed 1 acquisition, including Olimmune. Scopus BioPharma offers products and services including CO-sTiRNA™ and MRI-1867. Scopus BioPharma operates in a competitive market with competitors including CLS Holdings USA, Purisys, MMJ, Averix Bio and Agritek Holdings, among others.
- Headquarter United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Scopus Biopharma, Inc.
-
Annual Revenue
$00as on Dec 31, 2022
-
Net Profit
$-11.61 M56.93as on Dec 31, 2022
-
EBITDA
$-11.71 M57.61as on Dec 31, 2022
-
Total Equity Funding
$9.34 M (USD)
in 4 rounds
-
Latest Funding Round
$6.35 M (USD), Series B
Jul 09, 2020
-
Investors
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Scopus BioPharma
Scopus BioPharma is a publicly listed company on the OTC with ticker symbol SCPS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Scopus BioPharma
Scopus BioPharma offers a comprehensive portfolio of products and services, including CO-sTiRNA™ and MRI-1867. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targeted immuno-oncology therapy for treating multiple cancers.
Therapeutic for serious diseases through research programs.
Funding Insights of Scopus BioPharma
Scopus BioPharma has successfully raised a total of $9.34M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $6.35 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $6.3M
-
First Round
First Round
(07 Aug 2019)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2020 | Amount | Series B - Scopus BioPharma | Valuation |
investors |
|
| Feb, 2020 | Amount | Series A - Scopus BioPharma | Valuation |
investors |
|
| Dec, 2019 | Amount | Series A - Scopus BioPharma | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Scopus BioPharma
Scopus BioPharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Olimmune. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Oligonucleotide therapeutics are developed for cancer and disease treatment.
|
0 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Scopus BioPharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Scopus Biopharma Comparisons
Competitors of Scopus BioPharma
Scopus BioPharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CLS Holdings USA, Purisys, MMJ, Averix Bio and Agritek Holdings, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cannabis-extracted products are manufactured, researched, and retailed.
|
|
| domain | founded_year | HQ Location |
Cannabis products are manufactured in Athens, United States.
|
|
| domain | founded_year | HQ Location |
Plant-derived cannabinoid therapeutics are developed for medical applications.
|
|
| domain | founded_year | HQ Location |
Vertically integrated production of CBD ingredients for pharmaceuticals and supplements.
|
|
| domain | founded_year | HQ Location |
Integrated business for cultivation of cannabis and supply of medical marijuana products
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Scopus Biopharma
Frequently Asked Questions about Scopus BioPharma
When was Scopus BioPharma founded?
Scopus BioPharma was founded in 2019.
Where is Scopus BioPharma located?
Scopus BioPharma is headquartered in United States.
Who is the current CEO of Scopus BioPharma?
Morris C Laster is the current CEO of Scopus BioPharma.
Is Scopus BioPharma a funded company?
Scopus BioPharma is a funded company, having raised a total of $9.34M across 4 funding rounds to date. The company's 1st funding round was a Series A of $1.91M, raised on Aug 07, 2019.
What does Scopus BioPharma do?
Scopus BioPharma was established in 2019 in the United States. Operations are conducted within the biopharmaceutical sector, where cannabis-derived drugs are manufactured. Focus is placed on the production of pharmaceutical products based on cannabis compounds. The company is led by CEO Morris C. Laster, with activities centered in the US geography. Services encompass drug development and manufacturing processes tailored to regulatory standards in the industry.
Who are the top competitors of Scopus BioPharma?
Scopus BioPharma's top competitors include MMJ, Purisys and CLS Holdings USA.
What products or services does Scopus BioPharma offer?
Scopus BioPharma offers CO-sTiRNA™ and MRI-1867.
Is Scopus BioPharma publicly traded?
Yes, Scopus BioPharma is publicly traded on OTC under the ticker symbol SCPS.
How many acquisitions has Scopus BioPharma made?
Scopus BioPharma has made 1 acquisition, including Olimmune.
What is Scopus BioPharma's ticker symbol?
The ticker symbol of Scopus BioPharma is SCPS on OTC.